BCAL Diagnostics presents successful quarterly activities report

BCAL Diagnostics Limited (ASX: $BDX) is pleased to present its quarterly activities report for the quarter ended 31 March 2024. The company has successfully completed the first two stages of the SENSIBLE study, refining the lipid panel for BREASTEST®. Additionally, the appointment of CEO Shane Ryan and Non-Executive Directors, progress in intellectual property, and accelerated sample collection have been key highlights.

Executive Commentary on Progress and Developments

As part of BCAL's commercialization strategy, Shane Ryan has been appointed as the Chief Executive Officer, bringing valuable experience from his previous role at GenesisCare. The successful completion of the SENSIBLE studies has significantly refined the lipid panel for BREASTEST®, reducing complexity, cost, and improving robustness. The progress in intellectual property, including the notice of intent to grant for an additional European patent, is a significant achievement. The accelerated sample collection and the establishment of a national network of Key Opinion Leaders are crucial steps in facilitating the introduction of BREASTEST® to the Australian market.

Summary of Quarterly Activities and Outlook

BCAL Diagnostics has made significant progress in refining the lipid panel for BREASTEST® through the successful completion of the SENSIBLE studies. The appointment of Shane Ryan as CEO and the addition of Non-Executive Directors, David Darling and former CEO John Hurrell, demonstrate the company's commitment to driving commercial launch and growth. The progress in intellectual property, with the notice of intent to grant for an additional European patent, further strengthens BCAL's position. The accelerated sample collection and the establishment of a national network of Key Opinion Leaders are expected to play a pivotal role in the successful introduction of BREASTEST® to the Australian market. With $3.3 million cash at bank as at 31 March 2024, BCAL is well-positioned to continue its development activities and drive towards the commercial launch of BREASTEST® in late 2024.